経口マグネシウム療法は,冠動脈疾患の患者の内皮機能を改善します

M Shechter¹, M Sharir, M J Labrador

¹Preventive & Rehabilitative Cardiac Center and the Atherosclerosis Research Center, Cedars-Sinai Burns and Allen Research Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. shechtes@netvision.net.il

Circulation

|November 9, 2000

まとめ

マグネシウムサプリメントは,安定した冠動脈疾患 (CAD) の患者の内皮機能と運動耐性を改善しました. この経口マグネシウム療法により,研究グループでは腕動脈の血管拡張と運動能力が向上しました.

科学分野:

心血管医学心血管医学
栄養科学とは,栄養科学である.
生理学生理学とは

背景:

マグネシウムは,カルシウムの生理学的作用を阻害する役割を果たします.
安定した冠動脈疾患 (CAD) の患者における内皮機能と運動耐性に対するマグネシウム補給の効果は,依然として過小評価されています.

研究の目的:

安定した冠動脈疾患 (CAD) の患者の内皮機能と運動耐性に対する経口マグネシウムサプリメントの影響を評価する.

主な方法:

ランダム化,ダブルブラインド,プラセボ対照試験で,6ヶ月間にわたって50人の安定したCAD患者が参加しました.
評価された内皮に依存する腕動脈の流動媒介血管拡張 (FMD) と内皮に依存しないニトログリセリン媒介血管拡張は,超音波を用いた.
細胞内マグネシウム濃度 ([Mg2+) ]) を測定し,ブルースプロトコルによる運動耐性を測定した.

主要な成果:

マグネシウム療法は,プラセボと比較して,細胞内マグネシウム濃度を有意に増加させた.
マグネシウム群 (15.5+/-12.0%,P=0.02) とプラセボ群 (4.4+/-2.5%,P=0.78) の間で,介入後の FMD の有意な改善が観察されました.
マグネシウムを投与された患者は,より高い運動耐性 (9.3+/-2.0対7.3+/-3.1分,P=0.05) を示し,不全性STセグメントの変化が少なくなった (4対10患者,P=0.05).

結論:

経口マグネシウム療法は,CAD患者の腕動脈内皮機能の有意な改善と関連しています.
マグネシウムサプリメントは,運動耐性を向上させ,缺血性変化を減少させ,CADの管理に有益な役割を果たすことを示唆しました.
これらの発見は,マグネシウムが冠動脈疾患の臨床結果に肯定的な影響を与える可能性がある潜在的なメカニズムを示しています.

さらに関連する動画

06:35

Ultrasound Assessment of Endothelial Function: A Technical Guideline of the Flow-mediated Dilation Test

Published on: April 27, 2016

11:19

Isolation of Human Ventricular Cardiomyocytes from Vibratome-Cut Myocardial Slices

Published on: May 10, 2020

関連する概念動画

01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...

01:20

Angina V: Nursing Management

Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...

01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

関連する実験動画